Company Overview
Snapshot
Founded in September 2018 by Tal Gilat, Ibrahim Kassis, and Dimitrios Karussis, Neurogenesis operates with 1–10 employees. The company has raised $7.66M across two funding rounds from three investors. In May 2026, Neurogenesis secured a grant from the BIRD Foundation.
Business overview
Neurogenesis is a clinical-stage cellular therapy company focused on developing treatments for central nervous system diseases, including progressive multiple sclerosis and amyotrophic lateral sclerosis. The company utilizes a proprietary subpopulation of bone marrow stem cells, enhanced to become remyelinating and regenerative biofactory cells, through its NG CELL technology platform. Operating within the Health Tech & Life Sciences sector, Neurogenesis is advancing its products, NG-01 and NG-02, through clinical trials.
Strategic signal
In May 2026, Neurogenesis received a grant from the BIRD Foundation as part of new U.S.-Israel projects. This funding validates the company's innovative approach to cell therapy for neurodegenerative diseases and signals continued support for its research and development efforts, potentially accelerating its clinical programs and market entry.
Log in to access full profile ›Company Intelligence Q&A
- What is Neurogenesis's primary focus?
- Neurogenesis is a clinical-stage cellular therapy company dedicated to treating neurodegenerative diseases such as progressive multiple sclerosis and amyotrophic lateral sclerosis using proprietary bone marrow stem cells.
- When was Neurogenesis founded and by whom?
- Neurogenesis was founded in September 2018 by Tal Gilat, Ibrahim Kassis, and Dimitrios Karussis.
- How much capital has Neurogenesis raised to date?
- Neurogenesis has raised a total of $7.66 million across two funding rounds.
- What was a significant recent development for Neurogenesis?
- In May 2026, Neurogenesis secured a grant from the BIRD Foundation, supporting new U.S.-Israel projects in areas like smart agriculture and mental health.
- Which investors participated in Neurogenesis's March 2022 funding round?
- In March 2022, Neurogenesis received funding from investors including Rhodium and Excell Partners.